Other Seaport and Hemab target $180m IPOs as biotech listings accumulate Pharmaceutical TechnologySeaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.Read full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaceutical Technology Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Boehringer/Zealand dual-acting drug causes 16.6% weight lossNext: Novartis shares fall as Entresto sales weaken Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
